Skip to content
10-K

Annual Report

THESEUS PHARMACEUTICALS, INC.

0001558370-23-003251

← back to feed
Filed
Mar 9, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 1, 2023 43.56M sh
Shares Diluted FY 2022 · Dec 31, 2022 38.49M sh
Shares Diluted FY 2022 · Dec 31, 2021 9.63M sh
Capex FY 2022 · Dec 31, 2022 $455K
Operating Cash Flow FY 2022 · Dec 31, 2022 −$32.95M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$27.19M
Cash And Equivalents FY 2022 · Dec 31, 2022 $94.61M
Cash And Equivalents FY 2022 · Dec 31, 2021 $244.66M
Stockholders Equity FY 2022 · Dec 31, 2022 $207.62M
Stockholders Equity FY 2022 · Dec 31, 2021 $246.43M
Stockholders Equity FY 2022 · Dec 31, 2020 −$34.27M
Current Liabilities FY 2022 · Dec 31, 2022 $11.13M
Current Liabilities FY 2022 · Dec 31, 2021 $3.68M
Total Liabilities FY 2022 · Dec 31, 2022 $14.83M
Total Liabilities FY 2022 · Dec 31, 2021 $4.5M
Total Assets FY 2022 · Dec 31, 2022 $222.45M
Total Assets FY 2022 · Dec 31, 2021 $250.93M
Eps Diluted FY 2022 · Dec 31, 2022 −$1.31
Eps Diluted FY 2022 · Dec 31, 2021 −$2.84
Eps Basic FY 2022 · Dec 31, 2022 −$1.31
Eps Basic FY 2022 · Dec 31, 2021 −$2.84
Sga Expense FY 2022 · Dec 31, 2022 $18.39M
Sga Expense FY 2022 · Dec 31, 2021 $9.01M
Rd Expense FY 2022 · Dec 31, 2022 $35.7M
Rd Expense FY 2022 · Dec 31, 2021 $18.33M
Net Income FY 2022 · Dec 31, 2022 −$50.61M
Net Income FY 2022 · Dec 31, 2021 −$27.31M
Operating Income FY 2022 · Dec 31, 2022 −$54.09M
Operating Income FY 2022 · Dec 31, 2021 −$27.34M